Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 206.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 240,303 shares of the biotechnology company’s stock after buying an additional 161,910 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.85% of Arcturus Therapeutics worth $1,473,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ARK Investment Management LLC lifted its position in Arcturus Therapeutics by 9.2% during the 3rd quarter. ARK Investment Management LLC now owns 1,872,721 shares of the biotechnology company’s stock valued at $34,514,000 after purchasing an additional 157,681 shares during the period. Amova Asset Management Americas Inc. boosted its stake in shares of Arcturus Therapeutics by 6.4% in the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,947,835 shares of the biotechnology company’s stock valued at $35,879,000 after purchasing an additional 117,632 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Arcturus Therapeutics by 6.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,947,835 shares of the biotechnology company’s stock worth $35,899,000 after buying an additional 115,368 shares during the period. Green Alpha Advisors LLC raised its stake in shares of Arcturus Therapeutics by 31.9% during the fourth quarter. Green Alpha Advisors LLC now owns 28,282 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,839 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Arcturus Therapeutics by 42.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock worth $143,000 after buying an additional 2,313 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ARCT. Citigroup reduced their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Piper Sandler dropped their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. B. Riley Financial assumed coverage on Arcturus Therapeutics in a research report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Roth Mkm assumed coverage on Arcturus Therapeutics in a research note on Thursday, January 22nd. They set a “buy” rating and a $20.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $7.85 on Thursday. The firm has a market capitalization of $223.10 million, a price-to-earnings ratio of -3.30 and a beta of 2.44. The company’s 50 day simple moving average is $7.37 and its 200 day simple moving average is $9.89. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $14.32 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. As a group, analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.